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Abstract
We report on a radiopharmaceutical imaging platform designed to capture the kinetics of cellular
responses to drugs.
Methods—A portable in vitro molecular imaging system, comprised of a microchip and a beta-
particle imaging camera, permits routine cell-based radioassays on small number of either
suspension or adherent cells. We investigate the response kinetics of model lymphoma and
glioblastoma cancer cell lines to [18F]fluorodeoxyglucose ([18F]FDG) uptake following drug
exposure. Those responses are correlated with kinetic changes in the cell cycle, or with changes in
receptor-tyrosine kinase signaling.
Results—The platform enables radioassays directly on multiple cell types, and yields results
comparable to conventional approaches, but uses smaller sample sizes, permits a higher level of
quantitation, and doesn’t require cell lysis.
Conclusion—The kinetic analysis enabled by the platform provides a rapid (~1 hour) drug
screening assay.
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INTRODUCTION
In vivo molecular imaging assays, employing a variety of probes of specific biological
processes, have been developed for Positron Emission Tomography (PET). The most
common probe in patients care and research is the glucose analog, 2-deoxy-2-[18F]fluoro-
deoxy-D-glucose ([18F]FDG) for imaging and measuring rates of glycolysis. In cancer
patients, [18F]FDG assays are used for diagnosis and assessing therapeutic responses (1).
Around 3,000 molecular imaging probes for PET have been reported for various metabolic
and other processes associated with disease states (1).
In vitro metabolic assays using radiolabeled probes have been adapted to 96-well plates and
microchip formats(2). We explore here the use of such assays for quantitating the kinetics of
cellular responses to targeted drugs. We first introduce a microfluidic chip design (the
RIMChip) that couples to a beta particle imaging camera (2–4) to form the betabox. The
betabox is designed for the quantitative analysis of the metabolic response of small numbers
of cells to pharmaceuticals. Most assay steps are similar to those of standard 96-well plate
radioassays, but require far fewer cells, permit quantitation of signal per cell, and utilize live
cells. The platform is validated on various adherent and suspension cancer cells. We
characterize the influence of the monocarboxylate transporter (MCT1) protein, as well as a
glycolytic inhibitor, on [18F]FDG uptake in isogenic liposarcoma cells. Using different
liposarcoma cells, we investigate the influence of deoxycytidine kinase (dCK)(5) on the
uptake of the deoxycytidine analog molecular imaging probe [18F]-FAC(6).
We then explore how certain cancer cell lines respond to two mechanistically distinct
targeted inhibitors. We quantitate the response kinetics of liposarcoma cells to gemcitabine
(7) by correlating cell-cycle arrest with [18F]FDG uptake. We then quantitate the kinetic
response of model glioblastoma multiforme (GBM) cancer cells to an epidermal growth
factor receptor (EGFR) inhibitor, by correlating changes in [18F]FDG uptake with the levels
of phosphoproteins associated with EGFR signaling. Glucose consumption consistently
provides a rapid (~30 min.) indicator of positive therapeutic response, and the betabox
platform provides a simple tool for quantitating those kinetics.
MATERIALS AND METHODS
Betabox platform
The RIMChip design and fabrication process requires standard photolithography and
elastomer molding methods, as described in the SI Text, Supporting Materials and Methods.
The beta particle imaging camera has been reported(3). For this work, the camera was
miniaturized to be portable and simple to operate. The betabox is assembled by mounting
the RIMChip directly onto the camera face.
Cell sample preparation, viability, and cell cycle assays
Liposarcoma cell lines LPS1 and LPS2 with dCK- and MCT1-knockdown, respectively,
were derived from patient samples. Lentiviral-based, shRNA-mediated knockdown of
MCT1 and dCK were described in (8) The murine leukemic lines (L1210 wt and
L1210-10K)(9) were a kind gift from Charles Dumontet (Université Claude Bernard Lyon I,
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Lyon, France) (10). The human lymphoma line CEM was purchased from ATCC
(#CCL-119) and the sub-line, CEM-dCK negative, was generated via selection with ara-C
(11) and was a gift of Margaret Black (Washington State University). A human leukemia T
cell line (Jurkat T) was purchased from ATCC. The human glioblastoma cell line U87
EGFRvIII/PTEN were prepared as described(12). The LIVE/DEAD® Viability/Cytotoxicity
Kit (Invitrogen) was used to distinguish live cells from dead cells. For the cell cycle assay,
2×106 cells were collected and washed with PBS. DNA content was determined through
staining with 50 μg/mL Propidium Iodide (Sigma) for L1210 cells or BrdU kit (R&D
Systems) for U87 EGFRvIII/PTEN cells. Data were acquired on 4 and 5-laser LSRII
cytometers (BD Biosciences) and analyzed as previously described (13).
Betabox radioassay
Cells were prepared at 3×106 cells per ml and injected into the RIMChip. For adherent cells,
the microchannels were coated with fibronectin. For the kinetics studies, 5mM 2-
deoxyglucose (2DG), 10 μM gemcitabine, or 5μM erlotinib, in RPMI 1640 or DMEM
medium supplemented with 10% FBS, was added to the cells for a designated period. After
a 4 hour incubation period in a CO2 incubator at 37°C, PBS was flushed through the
RIMChip to remove unattached cells. The radiolabeled imaging probe ([18F]FAC or
[18F]FDG) was then pipetted into the RIMChip microchannels, and the RIMChip was
incubated for 30 min and flushed with PBS twice followed by incubation with 1 μg/ml
Hoechst 33342 in DMEM medium supplemented with 10% FBS and 1% Pen/Strep. Finally,
the betabox was assembled for the imaging measurement. Cell numbers were determined on
a Nikon Eclipse Ti microscope using the DAPI channel.
Off-chip Radioassay
About 105 Cells were seeded into a 12 well plate and the radiopharmaceutical (10 μCi/ml
[18F]FAC or 10 μCi/ml [18F]FDG) was added to cells. The radioactivity of the lysed cells
was measured using a γ-counter. Detailed procedures are described in the SI Text,
Supporting Materials and Methods.
Phosphoprotein assay
Confluent petri dishes containing 5×106 cells were prepared. Lysis buffer (Cell Signaling)
with protease inhibitor (Roche) and phosphatase inhibitor (Sigma), was prepared according
to the manufacturer’s instructions. Following cell lysis, protein concentrations of cell lysates
were quantified with a BCA kit (Pierce). A panel of phosphoproteins from the lysates were
assayed using a multiplex antibody array (14) and sandwich-type enzyme-linked
immunoassays (ELISAs). All proteins in the panel were measured simultaneously from each
sample. The biomolecular reagents used are listed in SI table 1.
Data processing
The counts of emitted beta particles from each cell capture chamber were normalized to the
counted cell numbers to reflect the uptake of the radiolabeled imaging probe per cell. See
Supplemental Materials and Methods.
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RESULTS
Each RIMChip (Fig. 1) permits 4 repeats of 5 independent assays. Each assay microchannel
inlet contains a bubble depletion chamber and a debris-trapping filter (Fig. 1A, B and
Supplemental Fig. 1). These permit the use of standard micropipetting for cell and reagent
introduction. The 50 μm separation between the cell capture chamber floors and the camera
yields an 11-fold increase in signal level relative to previous designs (2), which used a
microscope cover slip as the chamber floor. Fibronectin coating of the microchannel
surfaces promoted attachment and spreading of the adherent cells (Supplemental Fig. 2), but
did not influence the uniformity of cell loading or the [18F]FDG uptake (Supplemental Fig.
3,4). Suspension cells were found to attach to the untreated hydrophobic PDMS surface.
(Supplemental Fig. 4)
Cells were counted within each cell capture chamber (Fig. 1C), before and after the
radioassay, to permit per cell quantitation of the radioassay results. Cell loading and
[18F]FDG uptake exhibited ~8% variations across the different cell capture chambers
associated with a single microchannel. For T cell assays (Fig. 1E), chambers with ~70–110
cells exhibited a ~30-fold higher signal than control chambers with zero cells.
We executed proof-of-principle betabox radioassays in which the glycolytic or nucleoside
salvage pathways were genetically or molecularly manipulated in isogenic adherent
liposarcoma cell lines (Fig. 2). We altered monocarboxylate transporter 1 (MCT-1) levels
via stable expression of shRNA, and examined the resulting changes in [18F]FDG uptake
(Fig. 2A). In these cells, MCT-1 enhances glycolytic flux, so knockdown of MCT1 should
result in reduction of [18F]FDG uptake. The RIMChip assays detected a 35% relative
decrease in [18F]FDG uptake between Scr and DMCT-1 cells. The conventional assays
revealed a 12.5% reduction (Fig. 2A). Introduction of the glycolytic inhibitor 2-deoxy-
glucose (2DG) resulted in a stronger (3–10 fold) repression of [18F]FDG uptake, as recorded
in the RIMChip assay and bulk assays, respectively (Fig. 2B).
Certain liposarcomas exhibit nucleoside salvage activity, which can be imaged using the
nucleoside analogue 1-(2′-deoxy-2′ [18F]fluoroarabinofuranosyl) cytosine ([18F]FAC)(8).
[18F]FAC is a substrate for enzyme dCK, and so dCK knockdown should exhibit decreased
[18F]FAC uptake. The third betabox validation study supported this hypothesis (Fig. 2C).
The betabox was also used for interrogating the kinetics of cellular responses to targeted
therapies. All time points in a given kinetics run are imaged simultaneously, for easy
comparisons. The influence of gemcitabine on L1210-wt leukemia cells was first studied.
Gemcitabine is an anti-cancer pro-drug nucleoside analogue that will impede the cell cycle
in dCK positive tumors(9). Since glucose metabolism can help fuel the cell cycle, we
reasoned that gemcitabine treatment could influence both [18F]FDG uptake and the cell
cycle. Indeed [18F]FDG uptake decreases upon cell exposure to gemcitabine, with first order
kinetics and a half-life (τ1/2) of ~30 minutes (Fig. 3A). Cell cycle arrest exhibits similar
kinetics (τ1/2 ~50 minutes), and lags about 25 minutes behind changes in [18F]FDG uptake
(Supplemental Fig.5 and 6).
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A second class of targeted drugs is aimed at blocking growth factor signaling of receptor
tyrosine kinases (RTKs). For example, the ATP-competitive EGFR tyrosine kinase inhibitor
Erlotinib inhibits wild type and mutant EGFR (EGFRvIII) signaling, inhibiting the
phosphorylation of kinases that represent downstream effectors of EGFR (15, 16), and thus
inhibiting the growth of PTEN expressing glioblastomas (12). An activated growth factor
signaling pathway implies energy flux through that pathway, so we reasoned that inhibiting
that pathway would likely reduce cellular glucose consumption. Thus, we treated EGFRvIII
and PTEN-expressing model glioblastoma multiforme (GBM) cell lines with erlotinib, and
measured [18F]FDG uptake kinetics, plus the levels of a panel of phosphoproteins that are
downstream effectors of EGFR (Fig. 3B and Supplemental Fig.7). The full panel of assayed
proteins is provided as Supplemental Table 1. Again, [18F]FDG uptake drops sharply within
30 min, but the kinetics yield behavior reminiscent of a damped oscillator. Interestingly, this
oscillatory behavior is reflected in the changing levels of the assayed phosphoproteins. The
protein phosphorylated-AMP activated protein kinase (p-Ampkα) functions as an energy
regulator within the cell(17). Its level appears to initially oscillate out of phase with
[18F]FDG uptake, implying a compensatory mechanism for loss of glucose consumption.
The levels of p-EGFR, pErk and p-mTOR oscillate mostly in phase with each other, and are
partially synchronized with changes in [18F]FDG uptake. The amplitude of the changing
levels of a given phosphoprotein may reflect its proximity to EGFR in the RTK signaling
pathway. For example, p-EGFR itself exhibits the largest amplitude response, with p-mTOR
exhibiting the weakest response. Over the course of the 4-hour drug treatment window, the
cell cycle was relatively unaffected (Supplemental Fig. 8).
DISCUSSION
The comparisons of Figure 2 between the betabox assays and the 12-well plate (bulk) assays
reveal qualitative, but not fully quantitative agreement between the two approaches. A
concern might be that since the RIMChip assays a relatively small number of cells, the
corresponding statistical spread of results would be significantly larger than for the bulk
assays. However, this spread, which should scale as the square root of the numbers of cells,
is not large. For the comparisons of Fig 2, 4 microchannels × 4 microchambers per channel
× 100 cells per microchamber yields a 2.5% error, relative to an expected ~0.5% error for a
(~50,000 cells) bulk assay. Cell counting errors for the RIMChip assays may add a few
additional percent, as will the experimental errors in manipulating the cells for the bulk
assay. Small variations in the 50 μm thick PDMS membrane separating the cells from the
camera can also contribute a few percent error. However, given that the two techniques have
independent sources of error, and that the RIMChip assays for ~50-fold fewer cell numbers,
the agreement between the two techniques is good. There is a flow cytometry-based assay
that utilizes a fluorophore-labeled [18F]FDG analogue, but recent literature(18) has called
into question the validity of that assay, and so we did not compare against it here.
The kinetic responses recorded in Figure 3 reveal that the [18F]FDG RIMChip assay
provides a rapid (<1 hour) tool for detecting the response of small cell numbers to a therapy.
However, the assays also reveal different response kinetics for the different cell lines and
drugs. An exact resolution of such responses can be accomplished by either capturing the
dynamic trajectories of individual cells(19), or the fluctuations of the functional proteins at
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the single cell level(20). Obviously, the RIMChip assay does not resolve such trajectories of
fluctuations, but the cited literature can provide some insight into the observed responses.
For example, the 1st order relaxation kinetics observed for the response of the L1210
leukemia cells to gemcitabine exposure is consistent with a transition between two distinct,
steady state descriptions of those cells. An alternative explanation, which we can rule out by
our observations, is that gemicitabine exposure killed a fraction of the cells. No dead cells
were detected during the course of the experiment. The oscillatory dynamics observed for
the erlotinib treated GBM cells imply that there are competing networks that influence the
kinetics. The overall result may be the same – i.e. the cells are switching between two states,
but that is not as clear from our data. Again, however, no dead cells were detected during the
course of the experiments.
CONCLUSION
The betabox platform, comprised of a microfluidic chip (the RIMChip) mated to a beta-
particle imaging camera, enables robust, user-friendly execution of sensitive and
quantitative cell-based radioassays. Each radioassay requires ~100 cells. Betabox
radioassays provide a useful and rapid screening platform for investigating the response of
various cell lines to mechanistically distinct, targeted drugs. The betabox platform provides
a rapid screening tool for a variety of drug/cell line combinations, as well as a powerful tool
for mechanistic investigations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The RIMChip design, operation, and betabox performance
(A) Each RIMChip microchannel represents a separate assay condition, and permits four
repeats per condition. A bubble depletion chamber and post filter is incorporated at each
microchannel inlet. (B) Drawings (not to scale) and (C) photos of a cell capture chamber. A
cell suspension is injected through the inlets. Adherent cells attach to the bottom of the
fibronectin-treated microwells. The waffle structured walls provide structural integrity, and
prevent the cells from being disturbed by flowing solutions. (D) Photograph of a RIMChip
and a sample betabox radioassay revealing signal from a 4 microchamber microchannel. (E)
Statistics of cell loading (shown at two stages of a betabox assay) and statistics of the
radioassay signal, averaged over the cells with chambers (S) and those without (N). The bar
heights and uncertainties are calculated using the 4 cell capture chambers associated with a
given microchannel.
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Figure 2.
Validations of the RIMChip via genetic and molecular manipulation of glycolytic flux and
nucleoside salvage activity in betabox assays, with comparisons against standard assays. (A)
[18F]FDG uptake betabox radioassays of wild type LPS2 cells (Scr) (grey bars) and MCT1
knockdown LPS2 cells (DMCT-1). The betabox data uncertainties reflect the statistics from
16 microchambers (8 microchambers from two RIMChips) of measurements for each cell
line. The β camera image is of one such assay; the middle row is a 0-cell control. (B)
[18F]FDG assay on the same cells showing the influence of the glycolytic inhibitor 2DG. (C)
[18F]FAC uptake betabox radioassays on wild-type and dCK-1 knockout LPS1 cells.
Microchambers containing the dCK-1 knockout cells are in rows 2 and 4 from the top, row 5
is a control. The error bars represent the standard error of the mean. P-values: * = .05; **= .
01; *** = .001.
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Figure 3.
Betabox assays, correlated with other functional assays, for gauging the response of cancer
cells to targeted drugs. For these plots, the y-axis is % of the initial level (defined at the time
=0 point) to allow for all data to be co-represented on the same plots. (A) The kinetics of
[18F]FDG uptake and cell cycle arrest (measured using flow cytometry) following
gemcitabine treatment of L1210-wt leukemia cells. The solid lines are first order kinetic fits.
(B) The kinetics of [18F]FDG uptake compared with the dynamics of phospho-protein levels
within the RTK signaling pathway of U87 EGFRvIII PTEN GBM cells upon erlotinib
treatment. The lines connecting the data points are to guide the reader. Error bars indicate
average values from three repeat assays.
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